NDA 213972 · Iterum Therap
Orlynvah
Probenecid, Sulopenem Etzadroxil · Oral
NovelPriority reviewCDER novel approval, Oct 25, 2024: To treat uncomplicated urinary tract infections (uUTI)
Last checked: Nov 19, 2026Latest source record: Dec 23, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Oct 25, 2024
Approved uses
1
Original approval plus efficacy supplements
Registered trials
69
10 Phase 3, 6 recruiting
FAERS reports
2
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 6, 2025.
ORLYNVAH, a combination of sulopenem etzadroxil, a penem antibacterial, and probenecid, a renal tubular transport inhibitor, is indicated for the treatment of uncomplicated urinary tract infections (uUTI) caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women who have limited or no alternative oral antibacterial treatment options. ( 1.1 ) Limitations of Use ORLYNVAH is not indicated for the treatment of: Complicated urinary tract infections (cUTI) or as step-down treatment after intravenous antibacterial treatment of cUTI. ( 1.1 , 14.2 ) Complicated intra-abdominal infections (cIAI) or as step-down treatment after intravenous antibacterial treatment of cIAI. ( 1.1 , 14.3 ) Usage to Reduce Development of Drug-Resistant Bacteria To reduce the development of drug-resistant bacteria and maintain the effectiveness of ORLYNVAH and other antibacterial drugs, ORLYNVAH should be used only to treat uUTI that are proven or strongly suspected to be caused by susceptible bacteria. Culture and susceptibility information should be utilized in selecting or modifying antibacterial therapy. ( 1.2 , 5.5 ) 1.1 Uncomplicated Urinary Tract Infections ORLYNVAH is indicated for the treatment of uncomplicated urinary tract infections (uUTI) caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women who have limited or no alternative oral antibacterial treatment options. Limitations of Use ORLYNVAH is not indicated for the treatment of: Complicated urinary tract infections (cUTI) or as step-down treatment after intravenous antibacterial treatment of cUTI [see Clinical Studies ( 14.2 )]. Complicated intra-abdominal infections (cIAI)) or as step-down treatment after intravenous...
Mechanism: ORLYNVAH is a combination of sulopenem etzadroxil, a penem antibacterial drug [see Microbiology 12.4 ] and probenecid, a renal tubular transport inhibitor. Probenecid inhibits OAT3-mediated renal clearance of sulopenem, resulting in increased plasma concentrations of sulopenem .
Therapeutic areas: Infectious disease and vaccines · Kidney and urology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 25, 2024 Original approval · Type 1 - New Molecular Entity and Type 4 - New Combination · priority review NovelLabelLetterReview
1 products under this application
- ORLYNVAH · PROBENECID 500MG; SULOPENEM ETZADROXIL 500MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Probenecid" as an intervention, any sponsor and status, largest first.
- Therapeutics for Moderate and Severe DenguePivotal-lookingNot yet recruiting
Oxford University Clinical Research Unit, VietnamAcademic, hospital or other
NCT07543458 · 8,800 participants (planned) · Start Oct 1, 2026 · Primary completion Jul 31, 2030
Drug: Placebo; Dexamethasone and 2 more · For: Dengue; Severe Dengue; Mosquito-Borne Diseases and 5 more
Sites: Chittagong, Bangladesh; Dhaka, Bangladesh; São Paulo, Brazil · 18 sites in all
- Oral Sulopenem Versus Amoxicillin/Clavulanate for Uncomplicated Urinary Tract Infection in Adult WomenPivotal-lookingCompleted
Iterum Therapeutics, International LimitedIndustry
NCT05584657 · 2,229 participants · Start Oct 18, 2022 · Primary completion Nov 3, 2023
Drug: Sulopenem etzadroxil/probenecid; Amoxicillin/clavulanate · For: Urinary Tract Infections; Cystitis
Sites: Cullman, Alabama; Saraland, Alabama; Sheffield, Alabama · 167 sites in all
- Oral Sulopenem-etzadroxil/Probenecid Versus Ciprofloxacin for Uncomplicated Urinary Tract Infection in Adult WomenPivotal-lookingCompleted
Iterum Therapeutics, International LimitedIndustry
NCT03354598 · 1,671 participants · Start Aug 1, 2018 · Primary completion Jan 16, 2020
Drug: Sulopenem-Etzadroxil/Probenecid; Ciprofloxacin · For: Uncomplicated Urinary Tract Infections
Sites: Birmingham, Alabama; Phoenix, Arizona; Tolleson, Arizona · 60 sites in all
- Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Complicated UTI in AdultsPivotal-lookingCompleted
Iterum Therapeutics, International LimitedIndustry
NCT03357614 · 1,395 participants · Start Sep 18, 2018 · Primary completion Dec 14, 2019
Drug: Sulopenem; Sulopenem-Etzadroxil/Probenecid and 3 more · For: Complicated Urinary Tract Infections
Sites: Bellflower, California; Chula Vista, California; La Mesa, California · 32 sites in all
- Sulopenem Versus Ertapenem for Complicated Intra-abdominal Infection (cIAI)Pivotal-lookingCompleted
Iterum Therapeutics, International LimitedIndustry
NCT03358576 · 674 participants · Start Sep 18, 2018 · Primary completion Oct 2, 2019
Drug: Ertapenem; Sulopenem-Etzadroxil/Probenecid and 4 more · For: Intra Abdominal Infections
Sites: Chula Vista, California; Torrance, California; Idaho Falls, Idaho · 42 sites in all
- Efficacy of Probenecid on Cluster Seizures During Anti Seizure Medication Withdrawal in Presurgical Focal Epilepsy Video-EEG MonitoringPivotal-lookingRecruiting
Fondation Ophtalmologique Adolphe de RothschildResearch network
NCT07318870 · 600 participants (planned) · Start Aug 24, 2026 · Primary completion Sep 2029
Drug: Probenecid · For: Focal Epilepsy
Sites: Paris, France · 2 sites in all
- Oral Moxifloxacin Versus Cefazolin and Oral Probenecid in the Management of Skin and Soft Tissue Infections in the Emergency DepartmentPivotal-lookingCompleted
University of British ColumbiaAcademic, hospital or other
NCT00323219 · 390 participants · Start Jan 2004 · Primary completion Dec 2012
Drug: Cefazolin and Moxifloxacin · For: Cellulitis
Sites: Vancouver, Canada
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00000894 · 300 participants · Primary completion Jun 2000
Drug: Cidofovir; Probenecid and 1 more · For: Cytomegalovirus Retinitis; HIV Infections
Sites: Los Angeles, California; Miami, Florida; Atlanta, Georgia · 12 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- culture urine positive2
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2026 | 2 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Clinical pharmacokinetics of cefixime: a systematic review.
Ajmal M, Zamir A, Rehman AU, et al. · Xenobiotica 2023 · Systematic Review
- Sulopenem versus Amoxicillin/Clavulanate for the Treatment of Uncomplicated Urinary Tract Infection.
Puttagunta S, Aronin SI, Gupta J, et al. · NEJM Evid 2025 · Clinical Trial, Phase III, Comparative Study
- Sulopenem for the Treatment of Complicated Urinary Tract Infections Including Pyelonephritis: A Phase 3, Randomized Trial.
Dunne MW, Aronin SI, Das AF, et al. · Clin Infect Dis 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Sulopenem or Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infections in Women: A Phase 3, Randomized Trial.
Dunne MW, Aronin SI, Das AF, et al. · Clin Infect Dis 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Interventions for tophi in gout.
Sriranganathan MK, Vinik O, Bombardier C, et al. · Cochrane Database Syst Rev 2014 · Research Support, Non-U.S. Gov't, Systematic Review
- Antibiotics for gonorrhoea in pregnancy.
Brocklehurst P · Cochrane Database Syst Rev 2002 · Systematic Review
Sponsor: Iterum Therap
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.